Market cap
$6 Mln
Recently Viewed
Clear All$0.38
$0.01
(2.63%)
As on 30-Apr-2026 11:27EDT
Market cap
$6 Mln
Revenue (TTM)
$2 Mln
P/E Ratio
--
P/B Ratio
1
Div. Yield
0 %
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-1.2 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-6
Debt to Equity
0.5
Book Value
$0.5
EPS
$-1
Face value
--
Shares outstanding
14,415,128
CFO
$-42.58 Mln
EBITDA
$-53.78 Mln
Net Profit
$-71.54 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
CollPlant Biotechnologies - ADR
| -72.7 | -38.7 | -80.2 | -82.7 | -61.8 | -51.8 | -- |
|
BSE Sensex
| -9.2 | 6.9 | -6.5 | -4.2 | 8.0 | 9.1 | 11.6 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|
|
CollPlant Biotechnologies - ADR
| -61.1 | -23.5 | -49.0 | 51.9 | 88.9 | 35.7 |
|
S&P Small-Cap 600
| 4.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
CollPlant Biotechnologies - ADR
|
0.4 | 6.0 | 2.4 | -11.5 | -475.0 | -117.6 | -- | 1.0 |
| 2.6 | 293.1 | 72.8 | 35.3 | 0.0 | 44.8 | 8.2 | 2.7 | |
| 0.8 | 214.2 | 0.0 | 1,235.5 | -- | 126.2 | 0 | 0.1 | |
| 0.8 | 9.5 | 3.9 | -8.5 | -318.9 | 1107 | -- | 6.2 | |
| 0.6 | 4.1 | 0.0 | -10.3 | -- | -64.2 | -- | 0.3 | |
| 71.4 | 242.8 | 19.4 | -6.1 | -30.2 | -23.7 | -- | 10.6 | |
| 23.4 | 1,173.7 | 109.8 | -153.5 | -125.8 | 268.6 | -- | 19.3 |
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products... are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. The company offers regenerative dermal and soft tissue fillers; 3D-bioprinted regenerative breast implants; Collage, a combinant human Collagen type I solution; VergenixSTR, a soft tissue matrix for the treatment of tendinopathy; and VergenixFG, a wound care product for the treatment of deep surgical incisions and deep wounds. It also provides rhcollagen-based commercial bioink for regenerative medicine applications, such as Collink.3D 50L, a bioink in powder form; Collink.3D 90, an rhCollagen-based bioink solution for use in various 3D bioprinting applications; and Collink.3D 50, an rhCollagen-based bioink product. The company has collaboration agreements with AbbVie; STEMCELL; the Advanced Regenerative Manufacturing Institute; Stratasys; and RegenMed Development Organization. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel. Read more
CEO & Director
Mr. Yehiel Tal
CEO & Director
Mr. Yehiel Tal
Headquarters
Rehovot
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of CollPlant Biotechnologies Ltd - ADR is $0.38 (NASDAQ) as of 30-Apr-2026 11:27 EDT. CollPlant Biotechnologies Ltd - ADR has given a return of -61.78% in the last 3 years.
Since, TTM earnings of CollPlant Biotechnologies Ltd - ADR is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-1.46
|
2.76
|
|
2024
|
-2.38
|
2.94
|
|
2023
|
-10.01
|
2.48
|
|
2022
|
-5.43
|
2.85
|
|
2021
|
828.35
|
4.35
|
The 52-week high and low of CollPlant Biotechnologies Ltd - ADR are Rs 4.98 and Rs 0.28 as of 30-Apr-2026.
CollPlant Biotechnologies Ltd - ADR has a market capitalisation of $ 6 Mln as on 24-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in CollPlant Biotechnologies Ltd - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.